SecProbe.io

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 May 28, 2025

Gang Li
Chief Executive Officer
Chanson International Holding
B9 Xinjiang Chuangbo Zhigu Industrial Park
No. 100 Guangyuan Road, Shuimogou District
Urumqi, Xinjiang, China 830017

 Re: Chanson International Holding
 Registration Statement on Form F-1
 Filed May 19, 2025
 File No. 333-287404
Dear Gang Li:

 We have conducted a limited review of your registration statement and
have the
following comment(s).

 Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

 After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form F-1
Cover Page

1. We note your disclosure in the header that you are offering up to
25,000,000 Series B
 Warrants to purchase up to 75,000,000 shares of common stock.
Given the
 existence of the "alternate cashless exercise" provision, it appears
that those warrants
 will be exercised without any purchase payment. Accordingly, revise the
header to
 reflect that the Series B Warrants have a zero exercise price or no
exercise price
 option.
2. We note your references in your prospectus to an "alternative cashless
exercise" of the
 Series B Warrants. The term "cashless exercise" is generally understood
to allow a
 warrant holder to exercise a warrant without paying cash for the
exercise price and
 reducing the number of shares receivable by the holder by an amount
equal in value to
 May 28, 2025
Page 2

 the aggregate exercise price the holder would otherwise pay to exercise
the warrants.
 In cashless exercises, it is expected that the warrant holder receives
fewer shares than
 they would if they opted to pay the exercise price in cash. Please
clarify your
 disclosure throughout the prospectus by removing the references to
 "alternative cashless exercise" and exclusively using the term "zero
exercise price" or
 another appropriate term that conveys that, in addition to the company
receiving no
 cash upon the "alternative cashless exercise," the warrant holders would
be entitled to
 receive more shares than they would under the cash exercise terms.
3. With respect to the warrants with an alternative cashless exercise
feature, please
 revise the cover page narrative and Summary to explain, if true, that as
a result of this
 feature you do not expect to receive any cash proceeds from the exercise
of the
 Warrants because it is highly unlikely that a warrant holder would wish
to pay an
 exercise price to receive one share when they could choose the
alternative cashless
 exercise option and pay no money to receive more than one share.
Risk Factors, page 22

4. We note your disclosures indicate that under the cashless exercise
provision, your
 Series A and Series B warrant holders have the right to receive an
aggregate number
 of shares based on the formula provided. Please revise the header, the
cover page
 narrative and the Summary to highlight the maximum number of shares that
could be
 issued upon exercise of your Series A warrants and your Series B
warrants. For
 guidance, refer to Regulation S-K, Item 501(b)(2). Additionally,
disclose that the
 number of shares issuable on the exercise of the warrant under the
alternative cashless
 exercise provision increases as the stock price falls further below the
initial exercise
 price of the warrant.
5. We note your risk factor disclosure on page 21 concerning the potential
for substantial
 dilution from the "alternative cashless exercise" provision. With
reference to the
 disclosure on pages 21, please revise the risk factor disclosure, or add
a new risk
 factor, to address potential dilution from the reset provision that
could adjust upward
 the number of common shares underlying the Series B Warrants. The risk
factor
 should disclose the maximum number of shares that may be issuable upon
exercise of
 the warrants.
6. Please include in your risk factor disclosure that the offering could
cause the
 company's common stock price to fall below the minimum bid price. We
note that on
 page 18, you received a notice from the Listing Qualifications
Department of
 Nasdaq that based upon the closing bid price of the Class A Ordinary
Shares of the
 Company for the last 30 consecutive business days, you no longer meet
the continued
 listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2) and
as a
 result, your shares could be delisted from Nasdaq. If you have any plans
to seek
 shareholder approval for a reverse stock split, please disclose these
plans in the
 registration statement, including the proposed ratio, if known.
 We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.
 May 28, 2025
Page 3

 Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

 Please contact Kristin Baldwin at 202-551-7172 or Asia Timmons-Pierce at
202-551-
3754 with any other questions.

 Sincerely,

 Division of
Corporation Finance
 Office of
Manufacturing
cc: Benjamin Yao
</TEXT>
</DOCUMENT>